`Dr. Reddy's Laboratories, Ltd., et al. v. Helsinn Healthcare S.A.
`Trial PGR2016-00007
`
`Page 1 of 2
`
`
`
`
`
`Receipt date: 03/27/2014
`
`
`
`
`
`33901830 ~ GAL}: 1628
`
`
`
`
`INFORMATION DISCLOSURE
`
`
`STATEMENT BY APPLICANT
`
`
`
`
`
`(Use as many sheets as necessary)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Application Number
`
`
`
`I’:"”"’9NDa‘edl
`
`
`‘'3
`?""e
`"V6" °’
`Art Unit
`
`
`
`
`
`
`
`
`
`Attorney Docket Number
`
`
`
`
`
`
`
`Complete if Known
`13/901,830
`
`
`
`
`
`
`
`gay 24tC2E$ERAR|
`
`'°l9'°
`1628
`
`Shir|ey V_ GEMBEH
`
`
`
`
`244168-000007-US-9
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`NONPATENT LITERATURE DOCUMENTS
`
`
`
`Expert Report of Patrick P. DeLuca, Ph.D., dated September 9, 2013 (D.N.J. Case Nos. 11-3962 and 11-
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`5579; consolidated) (confidentiality designation and other portions redacted).
`
`
`
`
`
`
`
`
`Expert Report of Paul Myrdal, Ph.D., dated September 9, 2013 (D.N.J. Case Nos. 11-3962 and 11-5579;
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`consolidated) (confidentiality designation and other portions redacted).
`
`
`
`
`
`
`
`Complaint for patent infringement filed by Helsinn Healthcare S.A. and Roche Palo Alto LLC against
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Ben Venue Laboratories, Inc. d/b/a Bedford Laboratories regarding U.S. Patent Nos. 7,947,724, 7,947,725,
`
`
`
`
`
`
`
`
`
`
`
`
`7,960,424, and 8,518,981 dated September 25, 2013 (D. Del. Case No. 13-1612).
`
`
`
`
`
`
`
`
`
`
`
`Reply Expert Report of Patrick P. DeLuca, Ph.D., dated November 22, 2013 (D.N.J. Case Nos. 11-3962 and
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`11-5579; consolidated) (confidentiality designation redacted).
`
`
`
`
`
`Reply Expert Report of David G. Frame, Pharm. D., dated November 27, 2013 (D.N.J. Case Nos. 11-3962
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`and 11-5579; consolidated) (confidentiality designation redacted).
`
`
`
`
`
`
`Reply Expert Report of Jack Geltosky, Ph.D., dated November 22, 2013 (D.N.J. Case Nos. 11-3962 and
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`11-5579; consolidated) (confidentiality designation and other portions redacted).
`
`
`
`
`
`
`
`
`Reply Expert Report of Lee Kirsch, Ph.D., dated November 22, 2013 (D.N.J. Case No. 11-3962 and
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`11-5579; consolidated) (confidentiality designation redacted).
`
`
`
`
`
`Reply Expert Report of Paul Myrdal, Ph.D., dated November 22, 2013 (D.N.J. Case No. 11-3962 and
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`11-5579; consolidated) (confidentiality designation redacted).
`
`
`
`
`
`Reply Expert Report of Dr. Bert Spilker, dated November 22, 2013 (D.N.J. Case No. 11-3962 and 11-5579;
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`consolidated) (confidentiality designation and other portions redacted).
`
`
`
`
`
`
`
`Accord Healthcare, Inc. Paragraph IV Letter regarding U.S. Patent No. 8,518,981 dated October 2, 2013
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`(portions redacted).
`
`
`Bedford Laboratories division of Ben Venue Laboratories, Inc. Paragraph IV Letter regarding U.S. Patent
`
`
`
`
`
`
`
`
`
`
`
`
`
`No. 8,518,981 dated October 16, 2013 (portions redacted).
`
`
`
`
`
`
`
`
`Sandoz Inc. Paragraph IV Letter regarding U.S. Patent No. 8,518,981 dated December 16, 2013.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Aurobindo Pharma Ltd. Paragraph IV Letter regarding U.S. Patent Nos. 8,598,218 and 8,598,219 dated
`
`
`
`
`
`
`
`
`
`
`
`
`
`January 21, 2014 (portions redacted).
`
`
`
`
`
`Sandoz Inc. Paragraph IV Letter regarding U.S. Patent Nos. 8,598,218 and 8,598,219 dated February 3,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2014 (portions redacted).
`
`
`
`Bedford Laboratories division of Ben Venue Laboratories, Inc. Paragraph IV Letter regarding U.S. Patent
`
`
`
`
`
`
`
`
`
`
`
`
`
`Nos. 8,598,218 and 8,598,219 dated February 6, 2014 (portions redacted).
`
`
`
`
`
`
`
`
`
`
`Defendants Aurobindo Pharma Ltd.‘s and Auromedics Pharma LLC‘s Amended Answer, Affirmative
`
`
`
`
`
`
`
`
`
`
`
`Defenses, and Counterclaims regarding U.S. Patent Nos. 7,947,724, 7,947,725, 7,960,424, 8,518,981,
`
`
`
`
`
`
`
`
`
`
`8,598,218, and 8,598,219, dated February 11, 2014 (D. Del. Case No. 13-688).
`
`
`
`
`
`
`
`
`
`
`
`Ben Venue Laboratories, |nc.‘s Answer and Counterclaims to Amended Complaint regarding U.S. Patent
`
`
`
`
`
`
`
`
`
`
`
`
`
`Nos. 7,947,724, 7,947,725, 7,960,424, 8,518,981, 8,598,218, and 8,598,219, dated February 24, 2014 (D.
`
`
`
`
`
`
`
`
`
`
`
`
`Del. Case No. 13-1612).
`
`
`
`
`Complaint for Patent Infringement filed by Helsinn Healthcare S.A. and Roche Palo Alto LLC against Accord
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Healthcare, Inc. and Intas Pharmaceuticals Ltd regarding U.S. Patent Nos. 8,598,218 and 8,598,219 dated
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`December 27, 2013 (D. Del. Case No. 13-2101).
`
`
`
`
`
`
`
`Cipla Limited Paragraph IV Letter regarding U.S. Patent Nos. 7,947,724, 7,947,725, 7,960,424, 8,518,981,
`
`
`
`
`
`
`
`
`
`
`
`
`8,598,218, and 8,598,219 dated February 24, 2014 (portions redacted).
`
`
`
`
`
`
`
`
`
`Dr. Reddy's Laboratories, Ltd.‘s and Dr. Reddy's Laboratories, |nc.‘s Invalidity Contentions regarding U.S.
`
`
`
`
`
`
`
`
`
`
`
`
`Patent Nos. 8,518,981, 8,598,218, and 8,598,219 dated March 17, 2014 (D.N.J. Case No. 13-5815)
`
`
`
`
`
`
`
`
`
`
`
`
`
`(confidentiality designation and other portions redacted).
`
`
`
`
`
`
`Sandoz |nc.‘s Invalidity Contentions Pursuant to L. Pat. R. 3.3 and 3.6(c) regarding U.S. Patent Nos.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`8,518,981, 8,598,218, and 8,598,219 dated March 17, 2014 (D.N.J. Case No. 13-5815) (confidentiality
`
`
`
`
`
`
`
`
`
`
`
`
`
`designation and other portions redacted).
`
`
`
`
`
`Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd.‘s Invalidity Contentions Pursuant
`
`
`
`
`
`
`
`
`
`
`
`to L. Pat. R. 3.6(c) regarding U.S. Patent Nos. 8,518,981, 8,598,218, and 8,598,219 dated March 17,2014
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`(D.N.J. Case No. 13-5815) (confidentiality designation and other portions redacted).
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`\l(73l\)
`
`\l(73 01
`
`766
`
`767
`
`768
`
`769
`
`770
`
`771
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`772
`
`773
`
`774
`
`775
`
`Examiner
`
`I’
`‘\
`/ ,1‘. AI’
`if“ ;
`/"{"‘i
`Date
`
`
`
`Wet utmbtht at -10%-4: -
`
`
`
`
`
`EXAMINER:
`Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`citation if not in conformance and not considered.
`Include copy of this form with next communication to applicant.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`ALL REFERENCES CONSEBEREID EXCEPT WHERE UNEE) THRQUGH.
`
`
`
`/SQ./’
`
`
`
`Page 2 of 2
`
`Page 2 of 2